Levetiracetam Micro Labs (Levetiracetam)

Levetiracetam binds selectively to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates the exocytosis of excitatory neurotransmitters, stabilizing neuronal firing and reducing hyper‑excitability in the brain. By dampening abnormal synaptic activity, the drug helps prevent the initiation and spread of seizure activity.

The appropriate dose of levetiracetam is determined individually by a qualified prescriber based on factors such as the patient’s age, weight, renal function, and seizure type. Healthcare professionals calculate the loading and maintenance doses according to clinical guidelines and adjust them as needed to achieve optimal seizure control while minimizing adverse effects.

Safety data for levetiracetam in pregnancy and lactation are limited. It is classified as a pregnancy category where use is considered only when the potential benefit to the mother outweighs possible risks to the fetus. Breastfeeding mothers should consult their physician, as the drug can be excreted in breast milk and may affect the infant.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the inquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with older agents such as carbamazepine or phenytoin, levetiracetam has a relatively simple pharmacokinetic profile, minimal protein binding, and fewer drug‑enzyme interactions. It is often preferred for patients who require rapid intravenous administration or who have experienced adverse effects with other anticonvulsants, though individual response and tolerability vary.

Levetiracetam Micro Labs should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the solution, and inspect the vial for particulate matter before use.

The product is supplied as a sterile injectable solution for intravenous infusion. It is typically administered by a healthcare professional using an infusion pump or syringe, following the prescriber’s recommended rate and dosage. Proper aseptic technique and line priming are essential to avoid contamination and ensure accurate delivery.

Serious adverse reactions, although uncommon, include severe skin disorders such as Stevens‑Johnson syndrome, hematologic abnormalities like thrombocytopenia, respiratory depression with rapid IV administration, anaphylactic shock, and emergence of suicidal thoughts or depressive symptoms. Prompt medical evaluation is required if any of these events occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of the formulation excipients. Caution is also advised for individuals with severe renal impairment who have not had dose adjustments, and for patients with a history of serious psychiatric disorders without close monitoring. The medication should only be used under medical supervision.